Anh Dang
Psychiatric/Mental Health · Astoria, NYNPI 1114261245
Payments from drug & device makers
Across 203 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$799
- Alkermes, Inc.$788
- Johnson & Johnson$580
- Teva Pharmaceuticals USA, Inc.$439
- Vanda Pharmaceuticals Inc.$291
- plus $542 from 7 others
What the payments were for
- Food & beverage$4,41796%
- Education$1874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 44 | $1,165 |
| Otsuka America Pharmaceutical, Inc. | 38 | $799 |
| Alkermes, Inc. | 38 | $788 |
| Johnson & Johnson | 22 | $580 |
| Teva Pharmaceuticals USA, Inc. | 23 | $439 |
| Vanda Pharmaceuticals Inc. | 19 | $291 |
| Indivior Inc. | 8 | $186 |
| Amgen | 1 | $148 |
| E.r. Squibb & Sons, L.L.C. | 2 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Noven Therapeutics, LLC | 3 | $53 |
| Lundbeck LLC | 1 | $22 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,603 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 36 | $90,357 |
| Abilify MaintenaAripiprazole | 28 | $68,864 |
| Lurasidone Hcl | 23 | $6,946 |
| Paliperidone ErPaliperidone | 13 | $3,271 |
| Haloperidol Decanoate | 24 | $1,141 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $612 |
| Bupropion Hcl SrBupropion Hcl | 26 | $587 |
| Olanzapine | 21 | $209 |
| Risperidone | 20 | $197 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $149 |
| Benztropine Mesylate | 32 | $145 |
| Trazodone Hcl | 12 | $124 |
| Buspirone Hcl | 14 | $78 |
| Mirtazapine | 14 | $64 |
| Fluoxetine Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $580 | $90,35736 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $799 | $68,86428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Astoria
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.